Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)
Withdrawn
University of Tennessee
Phase 4
2008-01-01
The purpose of this study is to test the safety and efficacy of fondaparinux in patients with
heparin-induced thrombocytopenia (HIT). The primary objective is to ensure that patients with
HIT who are treated with fondaparinux experience a prompt and complete recovery of their
platelet count, and the secondary objective is to determine if any new blood clots are formed
while receiving the fondaparinux and up to one month after study enrollment. This information
will be compared to a historical control.
Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)
Withdrawn
Methodist Healthcare
Phase 4
2008-01-01
The purpose of this study is to test the safety and efficacy of fondaparinux in patients with
heparin-induced thrombocytopenia (HIT). The primary objective is to ensure that patients with
HIT who are treated with fondaparinux experience a prompt and complete recovery of their
platelet count, and the secondary objective is to determine if any new blood clots are formed
while receiving the fondaparinux and up to one month after study enrollment. This information
will be compared to a historical control.
Argatroban Versus Lepirudin in Critically Ill Patients
Terminated
Heinrich-Heine University, Duesseldorf
Phase 4
2009-01-01
The purpose of this study is to test the hypotheses that argatroban significantly increases
efficacy and safety of renal replacement therapy measured as life time of haemodialysis
filters as compared to lepirudin
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
